---
title: "Retatrutide vs Semaglutide: One Receptor or Three"
canonical_url: https://peptidelibrary.app/blog/retatrutide-vs-semaglutide
description: "Semaglutide is an approved GLP-1 receptor agonist; retatrutide is an investigational triple agonist that adds GIP and glucagon. How the mechanisms differ, what each has been tested for, and what the first head-to-head trial, in type 2 diabetes, has reported so far."
updated: 2026-11-08
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Retatrutide vs Semaglutide: One Receptor or Three

Semaglutide is an approved GLP-1 receptor agonist; retatrutide is an investigational triple agonist that adds GIP and glucagon. How the mechanisms differ, what each has been tested for, and what the first head-to-head trial, in type 2 diabetes, has reported so far.

**Semaglutide activates one receptor and is an approved medicine; retatrutide activates three and is still in clinical trials.** Every other difference between them follows from those two facts.

The first direct comparison has reported, but only as a company press release and only in type 2 diabetes. No peer-reviewed paper has followed yet, and no comparison in people without diabetes exists.

> **One is approved, one is not.** Semaglutide is FDA-approved as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management and cardiovascular risk reduction. Retatrutide is an investigational drug with no FDA approval, and research vials sold under its name are not a licensed product. Nothing here is dosing guidance.

## What each one is

- **Semaglutide** is an acylated analogue of human GLP-1. Fatty-acid acylation extends its half-life to about a week, which is what makes once-weekly injection possible; it is also available as a daily oral tablet (Rybelsus). See the [semaglutide profile](https://peptidelibrary.app/library/semaglutide).
- **Retatrutide** (LY3437943) is a single fatty-acylated peptide from Eli Lilly that activates the GIP, GLP-1 and glucagon receptors, given once weekly in trials. See the [retatrutide profile](https://peptidelibrary.app/library/retatrutide) or the [plain-language introduction](https://peptidelibrary.app/blog/what-is-retatrutide).

[Tirzepatide](https://peptidelibrary.app/library/tirzepatide) sits between them: one molecule, two receptors (GIP and GLP-1). Retatrutide adds glucagon on top of that.

## One receptor versus three

Semaglutide's effects all run through the GLP-1 receptor. It enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and reduces appetite through central pathways. Its weight effect runs mainly through appetite and intake.

Retatrutide keeps that GLP-1 action and adds two more:

- **GIP receptor activation**, thought to act on adipose tissue metabolism and hindbrain signalling — the component tirzepatide adds over semaglutide.
- **Glucagon receptor activation**, which raises hepatic energy expenditure and promotes fat oxidation. This works on the output side of energy balance rather than intake.

The glucagon arm is the interesting contrast. Semaglutide *suppresses* glucagon secretion as part of its glucose-lowering effect; retatrutide deliberately *activates* the glucagon receptor. Glucagon raises blood glucose, so that activation carries hyperglycaemic potential, and balancing it with enough incretin activity is the central design problem of triple agonists. That retatrutide's type 2 diabetes trials measured glycated haemoglobin is partly a test of whether the balance holds.

The [retatrutide vs tirzepatide comparison](https://peptidelibrary.app/blog/retatrutide-vs-tirzepatide) isolates the glucagon step; the [tirzepatide vs semaglutide comparison](https://peptidelibrary.app/blog/tirzepatide-vs-semaglutide) isolates the GIP step.

## Side by side

|  | **Semaglutide** | **Retatrutide** |
| --- | --- | --- |
| Receptors | GLP-1 | GIP, GLP-1, glucagon |
| Origin | Acylated human GLP-1 analogue | Synthetic triple agonist (Lilly) |
| Molecular weight | 4113.58 g/mol | ~4731 g/mol |
| Half-life | ~7 days | ~6 days |
| Dosing interval | Once weekly (injection); daily (oral tablet) | Once weekly in trials |
| Regulatory status | FDA-approved (Ozempic, Wegovy, Rybelsus) | Investigational New Drug; not FDA-approved |
| WADA status | Permitted (monitoring programme) | Prohibited (S0) |
| Evidence level | FDA-approved labels | Clinical trials: phase 2 and several phase 3 trials published; US submission planned for Q1 2027 |
| Dose source | Prescribing information | Trial protocols only |

## What the trials and labels cover

### Semaglutide

Semaglutide's dosing comes from its FDA prescribing information, which differs by product and indication:

The pivotal obesity evidence includes **STEP 1**, a phase 3 double-blind trial in adults with a BMI of 30 or more, or 27 or more with a weight-related condition, without diabetes. Its pharmacokinetics have been systematically reviewed (Yang 2024), and specific safety questions, including pancreatitis (Masson 2024) and thyroid cancer risk (Feier 2024), have their own reviews. The [semaglutide dosage chart](https://peptidelibrary.app/blog/semaglutide-dosage-chart) lays out the label regimens.

### Retatrutide

Retatrutide has no label, so every dose figure comes from a trial:

- **Liver fat.** A phase 2 substudy measuring liver fat content in adults with obesity and metabolic dysfunction-associated steatotic liver disease over 48 weeks (Sanyal 2024).
- Every trial is on the [retatrutide clinical trials](https://peptidelibrary.app/library/retatrutide/clinical-trials) page.

The [retatrutide dosage chart](https://peptidelibrary.app/blog/retatrutide-dosage-chart) sets out each arm against its source.

## The head-to-head: TRANSCEND-T2D-2

**NCT06260722 (TRANSCEND-T2D-2)** is a phase 3, open-label trial in adults with type 2 diabetes on metformin, with or without an SGLT2 inhibitor.

| --- | --- | --- | --- |
| HbA1c change (baseline 8.3%) | −2.2 points | −2.2 points | −1.8 points |
| Body weight change (baseline 102.4 kg) | −19.5% | −20.9% | −9.4% |
| Stopped because of adverse events | 4.8% | 7.9% | 2.7% |

Source: Lilly topline release, 2026-10-28. Lilly states all figures are the efficacy estimand. Three limits matter:

- **Not peer-reviewed yet.** Toplines leave out most of the detail a paper reports.
- **Open-label.** Participants and investigators knew which drug was given.
- The trial says nothing direct about obesity without diabetes.

Outside this trial, any retatrutide-versus-semaglutide percentage is cross-trial arithmetic: STEP 1 ran for 68 weeks in adults without diabetes; TRIUMPH-1 ran for 80 weeks in a different population.

A randomised comparison of that kind is the evidence mechanism cannot replace.

## What the evidence does not show

- **Whether retatrutide beats semaglutide in people without diabetes.** TRANSCEND-T2D-2 was in type 2 diabetes and has reported only as a topline.
- **Long-term safety of retatrutide.** Semaglutide is approved and has dedicated safety reviews; retatrutide's full phase 3 safety data have not been published.
- **That indirect comparisons settle it.** A Bayesian network meta-analysis has ranked GLP-1 receptor agonists, dual agonists and retatrutide for weight loss (Sinha 2025). That is a useful hypothesis, but it depends on trials with different populations and durations being comparable.
- **Anything about research-market material.** Every result above comes from a specific pharmaceutical product under trial or label conditions.

## Side effects

Gastrointestinal effects dominate both. Semaglutide's reported effects include nausea, vomiting, diarrhoea, constipation, abdominal pain, decreased appetite and gastro-oesophageal reflux, with pancreatitis and diabetic retinopathy complications as rare events. Retatrutide's reported effects include nausea, diarrhoea, constipation and an increase in heart rate.

The detail is in the [semaglutide side effects](https://peptidelibrary.app/blog/semaglutide-side-effects) and [retatrutide side effects](https://peptidelibrary.app/blog/retatrutide-side-effects) guides.

> **Neither research vial is the trialled product.** Research vials sold as retatrutide are not Lilly's investigational drug; several DailyMed listings under its name come from a cross-border e-commerce labeller, and a DailyMed listing is not FDA approval. [Compounded semaglutide](https://peptidelibrary.app/blog/compounded-semaglutide) is also not Wegovy or Ozempic. Unregulated products may be mislabelled or contaminated. Retatrutide is prohibited in tested sport under WADA's S0 category.

## The vial math

For research-purpose concentration arithmetic, the calculation depends on vial mass and water volume alone. These are the reconstitution examples from our profiles:

| --- | --- | --- | --- | --- |

The same syringe mark means a different mass in each row, which is the point: units are volume, not dose. The [semaglutide calculator](https://peptidelibrary.app/calculator/semaglutide) and [retatrutide calculator](https://peptidelibrary.app/calculator/retatrutide) work through each vial, and the [insulin syringe units converter](https://peptidelibrary.app/calculator/insulin-syringe-units) explains the markings.

## Frequently asked questions

### What is the difference between retatrutide and semaglutide?

Semaglutide activates the GLP-1 receptor only. Retatrutide activates the GLP-1, GIP and glucagon receptors. Semaglutide is FDA-approved; retatrutide is investigational.

### Is retatrutide stronger than semaglutide?

In people without diabetes there is no direct comparison.

### Is there a trial comparing retatrutide and semaglutide?

Yes. Lilly reported topline results on 2026-10-28; no paper yet.

### Is retatrutide FDA-approved?

No. It is an investigational drug; Lilly plans to submit it to the FDA in the first quarter of 2027. See [is retatrutide FDA approved](https://peptidelibrary.app/blog/retatrutide-fda-approval).

### Are they allowed in sport?

Semaglutide is permitted by WADA and included in its monitoring programme. Retatrutide is prohibited under the S0 category.

> **Research and educational use only.** Peptide Library is an independent research and comparison platform and does not sell peptides. Nothing here is medical advice, dosing guidance, or a recommendation to administer any substance to a person or an animal. Consult a licensed clinician for anything concerning human health.

## Sources

- [Wilding JPH, Batterham RL, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.](https://pubmed.ncbi.nlm.nih.gov/33567185/)
- [WEGOVY (semaglutide) injection — FDA prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
- [OZEMPIC (semaglutide) injection — FDA prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79)
- [Yang XD, Yang YY. Clinical Pharmacokinetics of Semaglutide: A Systematic Review. Drug Des Devel Ther. 2024;18:2555-2570.](https://pubmed.ncbi.nlm.nih.gov/38952487/)
- [Masson W, Lobo M, et al. Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis. Endocrinol Diabetes Nutr (Engl Ed). 2024;71(3):124-132.](https://pubmed.ncbi.nlm.nih.gov/38555109/)
- [Feier CVI, Vonica RC, et al. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review. Int J Mol Sci. 2024;25(8).](https://pubmed.ncbi.nlm.nih.gov/38673931/)
- [Jastreboff AM, Kaplan LM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.](https://pubmed.ncbi.nlm.nih.gov/37366315/)
- [Rosenstock J, Frias J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544.](https://pubmed.ncbi.nlm.nih.gov/37385280/)
- [Sanyal AJ, Kaplan LM, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048.](https://pubmed.ncbi.nlm.nih.gov/38858523/)
- [Bajaj HS, Welch M, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026;407(10546):2402-2413.](https://pubmed.ncbi.nlm.nih.gov/42250575/)
- [Frías JP, Davies MJ, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515.](https://pubmed.ncbi.nlm.nih.gov/34170647/)
- [Sinha B, Ghosal S. Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA. Obesity (Silver Spring). 2025;33(11):2046-2054.](https://pubmed.ncbi.nlm.nih.gov/40685589/)
- [NCT06260722 — Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)](https://clinicaltrials.gov/study/NCT06260722)
- [Eli Lilly. TRANSCEND-T2D-2 topline release, 2026-10-28.](https://www.prnewswire.com/news-releases/lillys-retatrutide-delivered-greater-a1c-reduction-and-more-than-double-the-weight-loss-of-ozempics-highest-approved-dose-in-head-to-head-trial-302921328.html)
- [Jastreboff AM, et al. Retatrutide for Treatment of Obesity (TRIUMPH-1). N Engl J Med. 2026;395(18):1781-1793.](https://pubmed.ncbi.nlm.nih.gov/42814954/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
